Pacira BioSciences, Inc. (PCRX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Pacira BioSciences, Inc. stock $16.49, price $36.43, that is 54.7% below the price, quality 74 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $11.70 – $81.64 · fair‑value band $16.49 – $24.08 · the $36.43 price screens above the $16.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Pacira BioSciences in your weekly email
Every Wednesday you see whether Pacira BioSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Show moreShow less
The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis.
It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals.
The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Stock analysis
Pacira BioSciences, Inc. (PCRX) currently trades at $36.43, while our model-based Fair Value estimate is $16.49, 55% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $57.54 per share, and 5 of the 24 models we run sit above the $36.43 price.
Bear case: the Earnings-Based group reads lowest at $3.17, and 19 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $16.49 (bear) to $24.08 (bull), the price of $36.43 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Pacira BioSciences, Inc. reported revenue of $726M in FY2025 versus $542M in FY2021, a compound +7.6%/yr. Reported net income was $7.0M in FY2025, compounding −36.0%/yr from FY2021.
Key figures
Market cap $1.5B Small · P/E ratio 104.1 · P/S ratio 1.97 · EPS (TTM) $0.3500 · Net margin 2.0% · Return on equity 2.1% · Return on assets (EBIT) 2.3% (5-year average) · Operating margin 6.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 90% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −55%, PCRX screens richer than that median.
Fair Value models
Bear$16.49Fair Value $16.49Bull$24.08
Price $36.43 · Downside -54.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.3001 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$44.95$80.54$171.0875
Growth DCF$42.99$88.10$165.5674
5Y EBITDA Exit$31.87$62.28$106.3872
All 24 models by family
DCF Models
FCF DCF$44.95$80.54$171.0875
Owner Earnings$13.39$33.30$70.9470
5Y Revenue Exit$15.67$26.14$40.9871
5Y EBITDA Exit$31.87$62.28$106.3872
5Y P/E Exit$12.23$18.88$25.8071
10Y Revenue Exit$24.68$39.78$58.6466
10Y EBITDA Exit$35.77$67.62$121.0265
10Y P/E Exit$22.65$33.85$48.9064
Earnings-Based
Graham-Dodd$1.20$7.66$10.7163
Lynch FV$2.22$3.17$4.1261
PEG = 1.0$2.22$3.17$4.1257
EPVn/a$0.6300$1.3168
Multiples
P/E Multiple$2.91$3.88$4.8563
P/S Multiple$2.25$3.00$3.7558
P/B Multiple$25.77$34.37$42.9655
EV/EBIT$3.23$6.77$10.3262
EV/EBITDA$25.30$36.20$47.1067
EV/Revenue$0.1800$3.44$6.6946
Asset-Based
NCAV (Graham)$3.82$5.12$7.6454
Growth DCF
Growth DCF$42.99$88.10$165.5674
Rev-Margin DCF$15.67$26.98$43.0971
Economic Profit
Residual Income$10.18$10.61$11.5671
ROIC Compoundern/a$0.6300$1.3168
Growth Earnings
Growth-Adj P/E$3.20$4.58$5.9567
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
In the last 6 months, 3 officers or directors sold shares worth $660,710 and none bought.
SaleLauren RikerSenior Vice President, Finance4× since Jan 5, 2026: 17,531 shares, avg. $27.33$479,186Oct 8, 202610b5-1 plan
SaleJonathan SloninChief Medical Officer3× since Nov 17, 2025: 10,261 shares, avg. $23.43$240,432Aug 17, 202610b5-1 plan
SaleKristen WilliamsChief Administrative Officer2× since Feb 2, 2026: 23,396 shares, avg. $21.29$498,171Jun 4, 202610b5-1 plan
SaleShawn CrossChief Financial Officer4× since Nov 10, 2025: 62,060 shares, avg. $24.51$1.5MApr 23, 202610b5-1 plan
SaleMark FroimsonDirector500 shares at $21.81$10,905Mar 17, 2026
Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.83/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Start year 2020 (pandemic). Over 10 years: +11.3% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−40.7% vs 13.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −0.2% a year for the price and +1.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Pacira BioSciences, Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−54.7% · Bottom 25%
Profitability
Return on equity (12 months)2.1% · Below median
Return on assets0.6% · Below median
Net margin (12 months)2.0% · Below median
Operating margin (12 months)6.2% · Below median
Growth and dividend
Revenue growth (quarter YoY)6.2% · Above median
Balance sheet
Debt / equity0.54× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pacira BioSciences, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/PCRX
Frequently asked questions
Is Pacira BioSciences, Inc. (PCRX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $16.49 versus a price of $36.43, about 55% lower (overvalued).
What is the fair value of PCRX?
Our model-based fair value for Pacira BioSciences, Inc. is $16.49 (as of Nov 6, 2026), built from audited fundamentals. The current price: $36.43.
What is the quality score of PCRX?
Pacira BioSciences, Inc. has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pacira BioSciences, Inc. (PCRX)?
Our model-based price target is the fair value of $16.49 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $16.49, optimistic scenario $24.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Pacira BioSciences, Inc. stock forecast for 2026?
Our models put fair value at $16.49, about 55% lower versus a price of $36.43 (overvalued). Cautious scenario $16.49, optimistic scenario $24.08. The calculation is refreshed regularly with new filings.
What is the revenue of Pacira BioSciences, Inc. (PCRX)?
Pacira BioSciences, Inc. reported trailing-twelve-month revenue of about $746M (latest available figure, as of Nov 6, 2026).
What growth is priced into Pacira BioSciences, Inc. (PCRX)?
For today's price to be fair in a discounted-cash-flow model, Pacira BioSciences, Inc. would have to grow free cash flow by +2.2 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of PCRX use?
Our models discount Pacira BioSciences, Inc. at 9.8 %: a base by market capitalisation (small), damped by beta 0.22, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pacira BioSciences, Inc. that is +2.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Pacira BioSciences, Inc. (PCRX) delivered so far?
Over the past 5 years revenue at Pacira BioSciences, Inc. grew +11.1 % a year. The price currently implies free-cash-flow growth of +2.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pacira BioSciences, Inc. (PCRX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Pacira BioSciences, Inc. (+2.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pacira BioSciences, Inc. (PCRX)?
The free-cash-flow yield on the price is 9.31 %: that much free cash flow Pacira BioSciences, Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pacira BioSciences, Inc. (PCRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pacira BioSciences, Inc. it is $16.49 per share (as of Nov 6, 2026), against a price of $36.43. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Pacira BioSciences, Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, PCRX trades above its calculated fair value: price $36.43, fair value $16.49, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PCRX?
No. The price is what the market pays today ($36.43); the fair value is what the company's own numbers justify ($16.49). For Pacira BioSciences, Inc. the two are $19.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pacira BioSciences, Inc. worth?
The market values Pacira BioSciences, Inc. at about $1.5B (market capitalisation, as of Nov 6, 2026). Per share that is $36.43; our models calculate a fair value of $16.49 per share.
What do the bullish and bearish scenarios say about PCRX?
Our models span a range for Pacira BioSciences, Inc.: cautious scenario $16.49, base $16.49, optimistic $24.08 per share (as of Nov 6, 2026, price $36.43). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PCRX?
Pacira BioSciences, Inc. trades at a price-to-earnings ratio of 104.1 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $16.49 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 30.6 (reported for FY2025: 227.7). Median P/E at fiscal year-end, 6 fiscal years (2018 to 2025), reported earnings, 4 of the years ex one-offs: 51.0. Other multiples: PEG 1.0, P/B 2.1, P/S 2.0, EV/EBITDA 13.6.
What is the PEG ratio of PCRX?
The PEG ratio of Pacira BioSciences, Inc. is 0.99 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Pacira BioSciences, Inc. (PCRX)?
Balance-sheet figures for Pacira BioSciences, Inc. (as of Nov 6, 2026): return on equity 2.1%, debt of 0.54 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is PCRX from its 52-week high?
Pacira BioSciences, Inc. trades at $36.43, at its 52-week high of $36.43 and 90% above the low of $19.16 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $16.49 is for.
Which stocks are comparable to Pacira BioSciences, Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pacira BioSciences, Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price $36.43, calculated fair value $16.49 (−55%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PCRX calculated?
We run Pacira BioSciences, Inc. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $16.49 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pacira BioSciences, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pacira BioSciences, Inc. (PCRX)?
The closing price on Nov 6, 2026 was $36.43. Our model-based fair value is $16.49, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pacira BioSciences, Inc. right now?
The price sits above even our optimistic bull case ($24.08). The favourable scenario is already priced in. Solid but not exceptional quality (74/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Pacira BioSciences, Inc.
How large is the market capitalisation of Pacira BioSciences, Inc. (PCRX)?
The market capitalisation of Pacira BioSciences, Inc. is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pacira BioSciences, Inc. (PCRX)?
The price-to-sales ratio of Pacira BioSciences, Inc. is 1.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pacira BioSciences, Inc. (PCRX)?
Earnings per share at Pacira BioSciences, Inc. are $0.3500 (price ÷ EPS = P/E 104.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pacira BioSciences, Inc. (PCRX)?
The net margin of Pacira BioSciences, Inc. is 2.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pacira BioSciences, Inc. (PCRX)?
The return on equity (ROE) of Pacira BioSciences, Inc. is 2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pacira BioSciences, Inc. (PCRX)?
On an EBIT basis the return on assets of Pacira BioSciences, Inc. is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pacira BioSciences, Inc. (PCRX)?
The operating margin of Pacira BioSciences, Inc. is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pacira BioSciences, Inc. (PCRX)?
Revenue at Pacira BioSciences, Inc. is growing +6.2% versus a year earlier (3y avg +2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pacira BioSciences, Inc. (PCRX)?
Earnings per share at Pacira BioSciences, Inc. are growing −30.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Pacira BioSciences, Inc. (PCRX) carry?
The net debt of Pacira BioSciences, Inc. is $296M (fiscal year 2025, ≈ 2.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pacira BioSciences, Inc. in the live analysis
One click puts Pacira BioSciences, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026